Contents
18 July 2018
Vol 10, Issue 450
Vol 10, Issue 450
Research Articles
- Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice
Silencing key neurons with botulinum toxin conjugates exerts long-lasting pain relief in mouse models of chronic pain.
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
- Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo
Human and mouse resident memory T cells are present in vitiligo lesions, and blocking IL-15 signaling provides long-lasting reversal of disease in a mouse model of vitiligo.
- PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Pharmacological PP2A activation is a druggable approach to overcome MEK inhibitor resistance.
Editors' Choice
- Play it again, Mom: How babies recognize melodies
Playing familiar songs during sleep increased hippocampal activation in toddlers.
- Re-engineering the heart with the correct components
Modulation of retinoic acid signaling generates atrial versus ventricular cardiomyocytes from human induced pluripotent stem cells.
- A cytokine duet regulates inflammatory bowel disease
Inhibition of IL-17F, but not IL-17A, promotes microbiota-mediated regulatory T cell generation in the colon and ameliorates intestinal inflammation in mice.
- A bullet against gallbladder cancer
ERBB2/3 mutations in gallbladder cancer are associated with immunosuppression and aggressive tumor development and can be targeted by ERBB2/3 inhibitors.
Erratum
About The Cover
ONLINE COVER Going Pain-Free with Botox. Depicted here is a molecule of botulinum toxin A, a neurotoxic product of the bacterium Clostridium botulinum that exerts its toxic effect by inhibiting acetylcholine release from neurons. This toxin is also known for its cosmetic applications (botox). Now, Maiarù et al. show in rodents that this toxin can be used for treating chronic pain. The authors developed botulinum toxin A–conjugated molecules that silenced specific pain–associated neuronal populations in two rodent models of pain. One injection of the toxin-conjugates exerted long lasting analgesia comparable to that of opioid treatments, suggesting that these molecules might be an effective alternative to opioids for treating pain. [CREDIT: DR_MICROBE/ISTOCK]
